Browsing by Author Filippatos, T.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 12 to 19 of 19 < previous 
TitleAuthor(s)Issue date???itemlist.???
High-Density Lipoprotein Subclasses in Patients with or without the Metabolic SyndromeLagos, K. G.; Gazi, I. F.; Kostapanos, M. S.; Filippatos, T.; Kazakou, P. S.; Rizos, C. V.; Tselepis, A. D.; Elisaf, M.24-Nov-2015-
LDL subfractions in patients with metabolic syndromeGazi, I.; Filippatos, T.; Bairaktari, E.; Kostara, C.; Tselepis, A.; Elisaf, M. S.24-Nov-2015-
Lipoprotein-associated phospholipase A(2) activity is a marker of small, dense LDL particles in human plasmaGazi, I.; Lourida, E. S.; Filippatos, T.; Tsimihodimos, V.; Elisaf, M.; Tselepis, A. D.24-Nov-2015-
Lipoprotein-associated phospholipase A2 activity (LP-PLA2) is a marker of small-dense LDL particlesGazi, I.; Lourida, E.; Filippatos, T.; Tsimihodimos, V.; Saougos, V.; Elisaf, M.; Tselepis, A.24-Nov-2015-
Plasma triglyceride levels and body mass index values are the most important determinants of pre beta-1 HDL concentrations in patients with various types of primary dyslipidemiaTsimihodimos, V.; Gazi, I.; Filippatos, T.; Kostapanos, M.; Lagos, K.; Kostara, C.; Tellis, C. C.; Elisaf, M.; Tselepis, A. D.24-Nov-2015-
Plasma Visfatin Concentration Is a Marker of an Atherogenic Metabolic ProfileFilippatos, T.; Tsimihodimos, V.; Derdemezis, C. S.; Gazi, I. F.; Saougos, V.; Tselepis, A. D.; Elisaf, M. S.24-Nov-2015-
Rosuvastatin administration decreases apolipoprotein CII and CIII serum levels in patients with primary dysilipidaemiaKostapanos, M.; Filippatos, T.; Gazi, I.; Saougos, V. G.; Milionis, H. J.; Kostara, C.; Bairaktari, E.; Elisaf, M. S.24-Nov-2015-
Treatment of hyperlipidaemia with fenofibrate and related fibratesFilippatos, T.; Milionis, H. J.24-Nov-2015-